C12N 2810/859
From immunoglobulins
Official title: from immunoglobulins
C12N2810/859 (From immunoglobulins) appears on 114 US grants and 171 published applications in this corpus.
Search patents in C12N- Granted patents
- 114
- Published applications
- 171
- Assignees
- 109
- Inventors
- 368
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 5 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 3 |
| 2002 | 7 | 6 |
| 2003 | 9 | 12 |
| 2004 | 5 | 10 |
| 2005 | 4 | 8 |
| 2006 | 5 | 8 |
| 2007 | 1 | 7 |
| 2008 | 3 | 7 |
| 2009 | 5 | 4 |
| 2010 | 4 | 4 |
| 2011 | 3 | 10 |
| 2012 | 2 | 6 |
| 2013 | 2 | 2 |
| 2014 | 5 | 11 |
| 2015 | 5 | 11 |
| 2016 | 6 | 8 |
| 2017 | 2 | 6 |
| 2018 | 6 | 6 |
| 2019 | 6 | 4 |
| 2020 | 3 | 6 |
| 2021 | 2 | 3 |
| 2022 | 2 | 4 |
| 2023 | 4 | 4 |
| 2024 | 3 | 6 |
| 2025 | 3 | 8 |
| 2026 | 2 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,622 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display28 Oct 2025US 12,455,280 B2Massachusetts Institute of Technology
- Adapter-based retroviral vector system for the selective transduction of target cells22 Jul 2025US 12,365,916 B2Miltenyi Biotec GmbH
- Ligand discovery and gene delivery via retroviral surface display11 Feb 2025US 12,222,347 B2Massachusetts Institute of Technology
- Modified aav particles16 Jul 2026US 2026/0200989 A1Hoffmann-La Roche Inc.
- Il13ra2-targeting herpes simplex virus and anti-il13ra2 antibody or antigen-binding fragment thereof11 Jun 2026US 2026/0159594 A1The University of Tokyo
- Adapter-based retroviral vector system for the selective transduction of target cells7 May 2026US 2026/0125703 A1Miltenyi Biotec GmbH
- Therapeutic recombinant viruses16 Apr 2026US 2026/0103727 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Ligand discovery and gene delivery via retroviral surface display29 Jan 2026US 2026/0029398 A1Massachusetts Institute of Technology
Most cited
By later US patents
- Adenovirus with modified binding moiety specific for the target cells150US 5,885,808 AImperial Cancer Research Technology, Ltd. · 1999
- Penton base protein and methods of using same136US 5,559,099 AGenVec, Inc. · 1996
- Non-invasive gene targeting to the brain83US 6,372,250 B1The Regents of the University of California · 2002
- Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein58US 5,712,136 AGenVec, Inc. · 1998
- Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand54US 5,993,800 ABristol-Myers Squibb Company · 1999